Amgen’s Repatha reduces heart attack risk in real-world study

Amgen announced a study showing evolocumab (Repatha) reduced heart attack risk by 20% compared to ezetimibe in patients with atherosclerotic cardiovascular disease. The real-world study followed 544,103 adults for up to 4 years, published in the American Journal of Preventive Cardiology. According to Amgen, the findings can help clinicians choose between these treatments.

Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, driven by sales growth in Repatha, UPLIZNA, and IMDELLTRA. GAAP EPS rose 19% to $7.08. Full-year revenue guidance is $38.9B-$39.7B. Free cash flow was $3.7B, with $13.2B in cash and $54B in debt.

The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.

Amgen (AMGN) reported Q3 earnings of $6.45 per share, beating estimates by 12%, with revenue of $10.4B, up 9% YoY. The company's stock has gained 72% since late 2024, driven by strong commercial performance and a robust pipeline. Analysts have mixed views on its valuation, with a forward P/E of 19.9x. Amgen has raised its dividend for 16 consecutive years, yielding 2.2%.

Amgen reported Q3 2026 revenue of $10.4 billion, an 8% increase. Seventeen medicines saw double-digit growth, and six key products grew 27% year-over-year, accounting for 70% of sales. The company also announced positive Phase 3 results for three treatments. Amgen highlighted its growth strategy and potential risks, including clinical, regulatory, and market factors.